License and Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Year Ended December 31,
Partner	Agreement	2016		2015		2014
AstraZeneca AB	MOVANTIK® and MOVANTIK® fixed-dose combination program	$	33,000	$	130,000	$	105,001
Roche	PEGASYS® and MIRCERA®		7,685		12,816		12,845
Amgen, Inc.	Neulasta®		5,000		5,000		5,000
Daiichi Sankyo Europe GmbH	ONZEALDTM (NKTR-102)		3,690		—		—
Bayer Healthcare LLC	BAY41-6551 (Amikacin Inhale)		1,429		1,919		4,717
Baxalta Incorporated	ADYNOVATE®		650		10,694		10,258
Other			8,928		5,175		15,468
License, collaboration and other revenue		$	60,382	$	165,604	$	153,289